Allt inom Corporate Information

First patient dosed in Nanexa’s Phase I trial of NEX-22 in type 2 diabetes

Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes has been initiated with dosing of the first patient. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system within the NEX-22 project. The study is a dose-escalation study aimed at evaluating the pharmacokinetic profile, safety and tolerability of different doses.

Bulletin from Nanexa’s Annual General Meeting

The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2024, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.